Shares in ReNeuron, a company working on stem-cell treatments for eye disease and strokes that is one-third owned by veteran investor Neil Woodford, rose more than 30 per cent on Tuesday, after it announced a licensing deal for its products to be developed and commercialised in China.
Fosun Pharma, a Chinese life sciences company, will licence the rights to two cell therapy programmes in a deal that will potentially net the UK-based biotech ￡80m, plus royalty payments.
Yifang Wu, President of Fosun Pharma, said ReNeuron’s licensed products and stem cell expertise would “bring a lot of strategic synergies with our current business, addressing huge unmet needs in the Chinese market”.
您已閱讀27%（688字），剩余73%（1849字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。